secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-09-11T23:59:59+00:00
Accession:  0001104659-23-099485
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics reports complete response in first lymphoma patient treated with MT-601 after CAR T relapse
--------------------------------------------------------------------------------

- First APOLLO trial patient with DLBCL, after 4 prior therapies including CAR T, achieved complete metabolic response at 8 weeks post 2nd MT-601 infusion.
- MT-601 dosed at 200 million cells without prior lymphodepletion; no treatment-related adverse events above Grade 1.
- Up to 60% of CAR T patients relapse within one year, underscoring potential of MT-601 in this setting.
- Phase 1 APOLLO trial continues to enroll additional participants to evaluate safety and efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923099485/0001104659-23-099485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923099485/tm2325824d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-099485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer